Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Hikma Labs Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate

Not Applicable

Completed

Conditions: Asthma

Interventions: Drug: Fluticasone / Salmeterol
Drug: Advair Diskus 100/50
Drug: Placebo

First Posted Date: 2016-01-07

Last Posted Date: 2018-01-23

Lead Sponsor: Roxane Laboratories

Target Recruit Count: 1430

Registration Number: NCT02649478

Locations: 🇺🇸
Roxane Laboratories Research Site #30, Glendale, Arizona, United States
🇺🇸
Roxane Laboratories Research Site #46, Phoenix, Arizona, United States
🇺🇸
Roxane Laboratories Research Site #1, Surprise, Arizona, United States

and more 97 locations

Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fasted Conditions

Early Phase 1

Completed

Conditions: Dry Mouth

Interventions: Drug: Cevimeline

First Posted Date: 2013-07-19

Last Posted Date: 2018-01-23

Lead Sponsor: Roxane Laboratories

Target Recruit Count: 26

Registration Number: NCT01903122

Locations: 🇺🇸
Novum Pharmaceutical Research Services, Las Vegas, Nevada, United States

Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fed Conditions

Early Phase 1

Completed

Conditions: Dry Mouth

Interventions: Drug: Cevimeline

First Posted Date: 2013-07-19

Last Posted Date: 2018-01-23

Lead Sponsor: Roxane Laboratories

Target Recruit Count: 27

Registration Number: NCT01903109

Locations: 🇺🇸
Novum Pharmaceutical Research Services, Las Vegas, Nevada, United States

Crossover Bioequivalence Study of Irbesartan HCTZ 300/25 mg Tablets Under Fasted Conditions

Not Applicable

Completed

Conditions: Hypertension

Interventions: Drug: Irbesartan and Hydrochlorothiazide
Drug: Avalide

First Posted Date: 2012-10-23

Last Posted Date: 2018-01-23

Lead Sponsor: Roxane Laboratories

Target Recruit Count: 37

Registration Number: NCT01712139

Locations: 🇺🇸
Worldwide Clinical Trials Drug Development Solutions (formerly CEDRA Clinical Research), San Antonio, Texas, United States

Crossover Bioequivalence Study of Irbesartan 300 mg Tablets Under Fed Conditions

Not Applicable

Completed

Conditions: Hypertension

Interventions: Drug: Irbesartan
Drug: Avapro

First Posted Date: 2012-10-23

Last Posted Date: 2018-01-23

Lead Sponsor: Roxane Laboratories

Target Recruit Count: 34

Registration Number: NCT01712100

Locations: 🇺🇸
Worldwide Clinical Trials Drug Development Solutions (formerly CEDRA Clinical Research), San Antonio, Texas, United States

Crossover Bioequivalence Study of Irbesartan 300 mg Tablets Under Fasted Conditions

Not Applicable

Completed

Conditions: Hypertension

Interventions: Drug: Avapro
Drug: Irbesartan

First Posted Date: 2012-10-23

Last Posted Date: 2018-01-23

Lead Sponsor: Roxane Laboratories

Target Recruit Count: 33

Registration Number: NCT01712113

Locations: 🇺🇸
Worldwide Clinical Trials Drug Development Solutions (formerly CEDRA Clinical Research), San Antonio, Texas, United States

Crossover Bioequivalence Study of Irbesartan Hydrochlorothiazide 300/25 mg Tablets Under Fed Conditions

Not Applicable

Completed

Conditions: Hypertension

Interventions: Drug: Irbesartan and Hydrochlorothiazide
Drug: Avalide

First Posted Date: 2012-10-23

Last Posted Date: 2018-01-23

Lead Sponsor: Roxane Laboratories

Target Recruit Count: 40

Registration Number: NCT01712126

Locations: 🇺🇸
Worldwide Clinical Trials Drug Development Solutions (formerly CEDRA Clinical Research), San Antonio, Texas, United States

Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fed Conditions

Phase 1

Completed

Conditions: Seizures

Interventions: Drug: Oxcarbazepine

First Posted Date: 2012-10-10

Last Posted Date: 2018-01-23

Lead Sponsor: Roxane Laboratories

Target Recruit Count: 59

Registration Number: NCT01703468

Locations: 🇺🇸
Worldwide Clinical Trials Drug Development Solutions (formerly CEDRA Clinical Research), San Antonio, Texas, United States

Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fasted Conditions

Phase 1

Completed

Conditions: Seizures

Interventions: Drug: Oxcarbazepine

First Posted Date: 2012-10-08

Last Posted Date: 2018-01-23

Lead Sponsor: Roxane Laboratories

Target Recruit Count: 64

Registration Number: NCT01702623

Locations: 🇺🇸
Worldwide Clinical Trials Drug Development Solutions (formerly CEDRA Clinical Research), San Antonio, Texas, United States

A Study of Oral Codeine Sulfate in Pediatric Patients With Post-procedural Pain

Phase 3

Terminated

Conditions: Pain

Interventions: Drug: Codeine

First Posted Date: 2012-08-31

Last Posted Date: 2018-10-02

Lead Sponsor: Roxane Laboratories

Target Recruit Count: 31

Registration Number: NCT01676493

Locations: 🇺🇸
Children's Medical Center Dallas, Dallas, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy